Staquis

RSS

Withdrawn

This medicine's authorisation has been withdrawn

crisaborole
MedicineHumanWithdrawn

Polish is available via eTranslation, the European Commission's machine translation service.

Translate to Polish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 31 January 2022, the European Commission withdrew the marketing authorisation for Staquis (crisaborole) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pfizer Europe MA EEIG, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Staquis was granted marketing authorisation in the EU on 27 March 2020 for the treatment of mild to moderate atopic dermatitis. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU. 

The European Public Assessment Report (EPAR) for Staquis is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (328.69 KB - PDF)

Zobacz

español (ES) (281.81 KB - PDF)

Zobacz

čeština (CS) (320.82 KB - PDF)

Zobacz

dansk (DA) (281.27 KB - PDF)

Zobacz

Deutsch (DE) (285.3 KB - PDF)

Zobacz

eesti (ET) (270.41 KB - PDF)

Zobacz

ελληνικά (EL) (329.52 KB - PDF)

Zobacz

français (FR) (283.57 KB - PDF)

Zobacz

hrvatski (HR) (303.39 KB - PDF)

Zobacz

italiano (IT) (280.3 KB - PDF)

Zobacz

latviešu (LV) (329.73 KB - PDF)

Zobacz

lietuvių (LT) (305.64 KB - PDF)

Zobacz

magyar (HU) (318.99 KB - PDF)

Zobacz

Malti (MT) (320.18 KB - PDF)

Zobacz

Nederlands (NL) (282.3 KB - PDF)

Zobacz

polski (PL) (321.05 KB - PDF)

Zobacz

português (PT) (283.06 KB - PDF)

Zobacz

română (RO) (303.92 KB - PDF)

Zobacz

slovenčina (SK) (319.54 KB - PDF)

Zobacz

slovenščina (SL) (317.49 KB - PDF)

Zobacz

suomi (FI) (279.2 KB - PDF)

Zobacz

svenska (SV) (281.27 KB - PDF)

Zobacz

Product information

български (BG) (1.77 MB - PDF)

Zobacz

español (ES) (652.9 KB - PDF)

Zobacz

čeština (CS) (854.6 KB - PDF)

Zobacz

dansk (DA) (701.91 KB - PDF)

Zobacz

Deutsch (DE) (631.59 KB - PDF)

Zobacz

eesti (ET) (632.47 KB - PDF)

Zobacz

ελληνικά (EL) (1.11 MB - PDF)

Zobacz

français (FR) (646.88 KB - PDF)

Zobacz

hrvatski (HR) (686.34 KB - PDF)

Zobacz

italiano (IT) (654.17 KB - PDF)

Zobacz

latviešu (LV) (954.3 KB - PDF)

Zobacz

lietuvių (LT) (666.03 KB - PDF)

Zobacz

magyar (HU) (907.86 KB - PDF)

Zobacz

Malti (MT) (990.45 KB - PDF)

Zobacz

Nederlands (NL) (743.33 KB - PDF)

Zobacz

polski (PL) (844.03 KB - PDF)

Zobacz

português (PT) (718.77 KB - PDF)

Zobacz

română (RO) (764.23 KB - PDF)

Zobacz

slovenčina (SK) (932.49 KB - PDF)

Zobacz

slovenščina (SL) (945.75 KB - PDF)

Zobacz

suomi (FI) (699.75 KB - PDF)

Zobacz

svenska (SV) (617.55 KB - PDF)

Zobacz

Íslenska (IS) (603.78 KB - PDF)

Zobacz

norsk (NO) (599.01 KB - PDF)

Zobacz
Latest procedure affecting product information:N/0006
01/10/2021
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (201.75 KB - PDF)

Zobacz

español (ES) (186.74 KB - PDF)

Zobacz

čeština (CS) (195.66 KB - PDF)

Zobacz

dansk (DA) (187.51 KB - PDF)

Zobacz

Deutsch (DE) (188.07 KB - PDF)

Zobacz

eesti (ET) (186.99 KB - PDF)

Zobacz

ελληνικά (EL) (201.24 KB - PDF)

Zobacz

français (FR) (187.58 KB - PDF)

Zobacz

hrvatski (HR) (186.48 KB - PDF)

Zobacz

italiano (IT) (186.31 KB - PDF)

Zobacz

latviešu (LV) (195.58 KB - PDF)

Zobacz

lietuvių (LT) (187.21 KB - PDF)

Zobacz

magyar (HU) (195.07 KB - PDF)

Zobacz

Malti (MT) (199.97 KB - PDF)

Zobacz

Nederlands (NL) (186.56 KB - PDF)

Zobacz

polski (PL) (195.15 KB - PDF)

Zobacz

português (PT) (186.88 KB - PDF)

Zobacz

română (RO) (186.68 KB - PDF)

Zobacz

slovenčina (SK) (195.31 KB - PDF)

Zobacz

slovenščina (SL) (193.6 KB - PDF)

Zobacz

suomi (FI) (186.56 KB - PDF)

Zobacz

svenska (SV) (186.08 KB - PDF)

Zobacz

Íslenska (IS) (187.47 KB - PDF)

Zobacz

norsk (NO) (191.95 KB - PDF)

Zobacz

Product details

Name of medicine
Staquis
Active substance
Crisaborole
International non-proprietary name (INN) or common name
crisaborole
Therapeutic area (MeSH)
Dermatitis, Atopic
Anatomical therapeutic chemical (ATC) code
D11AH06

Pharmacotherapeutic group

Other dermatological preparations

Therapeutic indication

Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ? 40% body surface area (BSA) affected.

Authorisation details

EMA product number
EMEA/H/C/004863
Marketing authorisation holder
Pfizer Europe MA EEIG

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Opinion adopted
30/01/2020
Marketing authorisation issued
27/03/2020
Revision
6

Assessment history

This page was last updated on

Share this page